Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States

INTRODUCTION: We assessed the impact of HER2-positive early breast cancer (EBC) treatment landscape changes following the introduction of pertuzumab and ado-trastuzumab emtansine (T-DM1) on cumulative population-level recurrences avoided since 2013 (first pertuzumab approval for EBC in the United St...

Descripción completa

Detalles Bibliográficos
Autores principales: Sussell, Jesse A., Press, David J., Hansen, Svenn A., Kim, Eunice, Du Toit, Yolande, Fung, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427558/
https://www.ncbi.nlm.nih.gov/pubmed/37358705
http://dx.doi.org/10.1007/s12325-023-02554-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427558/
https://www.ncbi.nlm.nih.gov/pubmed/37358705
http://dx.doi.org/10.1007/s12325-023-02554-6

Ejemplares similares